[1]
|
Xia, C., Dong, X., Li, H., et al. (2022) Cancer Statistics in China and United States, 2022: Profiles, Trends, and Deter-minants. Chinese Medical Journal, 135, 584-590. https://doi.org/10.1097/CM9.0000000000002108
|
[2]
|
中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南(2022年版) [J]. 中华肝脏病杂志, 2022, 30(4): 367-388.
|
[3]
|
Yang, J.D., Hainaut, P., Gores, G.J., Amadou, A., Plymoth, A. and Roberts, L.R. (2019) A Global View of Hepatocellular Carcinoma: Trends, Risk, Prevention and Management. Nature Reviews Gastroenterology & Hepatol-ogy, 16, 589-604. https://doi.org/10.1038/s41575-019-0186-y
|
[4]
|
Xu, F., Jin, T., Zhu, Y. and Dai, C. (2018) Immune Checkpoint Therapy in Liver Cancer. Journal of Experimental & Clinical Cancer Research, 37, Article No. 110. https://doi.org/10.1186/s13046-018-0777-4
|
[5]
|
Wilhelm, S.M., Adnane, L., Newell, P., Villanueva, A., Llovet, J.M. and Lynch, M. (2008) Preclinical Overview of Sorafenib, a Multikinase Inhibitor That Targets both Raf and VEGF and PDGF Receptor Tyrosine Kinase Signaling. Molecular Cancer Therapeutics, 7, 3129-3140. https://doi.org/10.1158/1535-7163.MCT-08-0013
|
[6]
|
Llovet, J.M., Ricci, S., Mazzaferro, V., et al. (2008) Soraf-enib in Advanced Hepatocellular Carcinoma. The New England Journal of Medicine, 359, 378-390. https://doi.org/10.1056/NEJMoa0708857
|
[7]
|
Yamamoto, Y., Matsui, J., Matsushima, T., et al. (2014) Lenvatinib, an Angiogenesis Inhibitor Targeting VEGFR/FGFR, Shows Broad Antitumor Activity in Human Tumor Xenograft Models Associated with Microvessel Density and Pericyte Coverage. Vascular Cell, 6, Article No. 18. https://doi.org/10.1186/2045-824X-6-18
|
[8]
|
Kudo, M., Finn, R.S., Qin, S., et al. (2018) Lenvatinib versus So-rafenib in First-Line Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Randomised Phase 3 Non-Inferiority Trial. The Lancet, 391, 1163-1173.
https://doi.org/10.1016/S0140-6736(18)30207-1
|
[9]
|
Li, X., Qiu, M., Wang, S., Zhu, H., Feng, B. and Zheng, L. (2020) A Phase I Dose-Escalation, Pharmacokinetics and Food-Effect Study of Oral Donafenib in Patients with Ad-vanced Solid Tumours. Cancer Chemotherapy and Pharmacology, 85, 593-604. https://doi.org/10.1007/s00280-020-04031-1
|
[10]
|
秦叔逵, 毕锋, 白玉贤, 盛泽林. 多纳非尼和索拉非尼头对头一线治疗晚期肝细胞癌的药代动力学参数比较研究[J]. 临床肿瘤学杂志, 2022, 27(6): 481-487.
|
[11]
|
Qin, S., Bi, F., Gu, S., et al. (2021) Donafenib versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial. Journal of Clinical Oncology, 39, 3002-3011. https://doi.org/10.1200/JCO.21.00163
|
[12]
|
Rahma, O.E. and Hodi, F.S. (2019) The Intersection be-tween Tumor Angiogenesis and Immune Suppression. Journal of Clinical Oncology, 25, 5449-5457. https://doi.org/10.1158/1078-0432.CCR-18-1543
|
[13]
|
Ferrara, N., Hillan, K.J. and Novotny, W. (2005) Bevaci-zumab (Avastin), a Humanized Anti-VEGF Monoclonal Antibody for Cancer Therapy. Biochemical and Biophysical Research Communications, 333, 328-335.
https://doi.org/10.1016/j.bbrc.2005.05.132
|
[14]
|
Chen, D.S. and Hurwitz, H. (2018) Combinations of Bevacizumab with Cancer Immunotherapy. The Cancer Journal, 24, 193-204. https://doi.org/10.1097/PPO.0000000000000327
|
[15]
|
Finn, R.S., Qin, S., Ikeda, M., et al. (2020) Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. The New England Journal of Medicine, 382, 1894-1905. https://doi.org/10.1056/NEJMoa1915745
|
[16]
|
Cheng, A.L., Qin, S., Ikeda, M., et al. (2022) Updated Efficacy and Safety Data from IMbrave150: Atezolizumab plus Bevacizumab vs. Sorafenib for Unresectable Hepatocellular Carcinoma. Journal of Hepatology, 76, 862-873.
https://doi.org/10.1016/j.jhep.2021.11.030
|
[17]
|
Gordan, J.D., Kennedy, E.B., Abou-Alfa, G.K., et al. (2020) Sys-temic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. Journal of Clinical Oncology, 38, 4317-4345. https://doi.org/10.1200/JCO.20.02672
|
[18]
|
中国临床肿瘤学会(CSCO). 原发性肝癌诊疗指南(2020) [M]. 北京: 人民出版社, 2020: 87-88.
|
[19]
|
Zhang, L., Mai, W., Jiang, W. and Geng, Q. (2020) Sintilimab: A Promising An-ti-Tumor PD-1 Antibody. Frontiers in Oncology, 10, Article ID: 594558. https://doi.org/10.3389/fonc.2020.594558
|
[20]
|
Ren, Z., Xu, J., Bai, Y., et al. (2021) Sintilimab plus a Bevacizumab Biosimilar (IBI305) versus Sorafenib in Unresectable Hepatocellular Carcinoma (ORIENT-32): A Randomised, Open-Label, Phase 2-3 Study. The Lancet Oncology, 22, 977-990. https://doi.org/10.1016/S1470-2045(21)00252-7
|
[21]
|
He, M., Li, Q., Zou, R., et al. (2019) Sorafenib plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma with Portal Vein Invasion: A Randomized Clinical Trial. JAMA Oncology, 5, 953-960. https://doi.org/10.1001/jamaoncol.2019.0250
|
[22]
|
Facciorusso, A., Abd El Aziz, M.A. and Sacco, R. (2019) Effi-cacy of Regorafenib in Hepatocellular Carcinoma Patients: A Systematic Review and Meta-Analysis. Cancers (Basel), 12, Article No. 36.
https://doi.org/10.3390/cancers12010036
|
[23]
|
Bruix, J., Qin, S., Merle, P., et al. (2017) Regorafenib for Patients with Hepatocellular Carcinoma Who Progressed on Sorafenib Treatment (RESORCE): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet, 389, 56-66. https://doi.org/10.3390/cancers12010036
|
[24]
|
Zhang, H. (2015) Apatinib for Molecular Targeted Therapy in Tumor. Drug Design, Development and Therapy, 9, 6075-6081. https://doi.org/10.2147/DDDT.S97235
|
[25]
|
Qin, S., Li, Q., Gu, S., et al. (2021) Apatinib as Second-Line or Later Therapy in Patients with Advanced Hepatocellular Carcinoma (AHELP): A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial. The Lancet Gastroenterology and Hepatology, 6, 559-568. https://doi.org/10.1016/S2468-1253(21)00109-6
|
[26]
|
Markham, A. and Keam, S.J. (2019) Camrelizumab: First Global Approval. Drugs, 79, 1355-1361.
https://doi.org/10.1007/s40265-019-01167-0
|
[27]
|
Qin, S., Ren, Z., Meng, Z., et al. (2020) Camrelizumab in Pa-tients with Previously Treated Advanced Hepatocellular Carcinoma: A Multicentre, Open-Label, Parallel-Group, Ran-domised, Phase 2 Trial. The Lancet Oncology, 21, 571-580.
https://doi.org/10.1016/S1470-2045(20)30011-5
|
[28]
|
Desai, J., Deva, S., Lee, J.S., et al. (2020) Phase IA/IB Study of Single-Agent Tislelizumab, an Investigational Anti-PD-1 Antibody, in Solid Tumors. The Journal for Immu-noTherapy of Cancer, 8, e000453.
https://doi.org/10.1136/jitc-2019-000453
|
[29]
|
Ducreux, M., Abou-Alfa, G.K., Ren, Z., et al. (2021) Results from a Global Phase 2 Study of Tislelizumab, an Investigational PD-1 Antibody, in Patients with Previously Treated Advanced Hepatocellular Carcinoma. ESMO World Congress on Gastrointestinal Cancer 2021, 30 June-3 July 2021, 1062.
|
[30]
|
Qin, S., Finn, R.S., Kudo, M., et al. (2019) RATIONALE 301 Study: Tislelizumab versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma. Future Oncology, 15, 1811-1822.
https://doi.org/10.2217/fon-2019-0097
|
[31]
|
El-Khoueiry, A.B., Sangro, B., Yau, T., et al. (2017) Nivolumab in Pa-tients with Advanced Hepatocellular Carcinoma (CheckMate 040): An Open-Label, Non-Comparative, Phase 1/2 Dose Escalation and Expansion Trial. The Lancet, 389, 2492-2502. https://doi.org/10.1016/S0140-6736(17)31046-2
|
[32]
|
Zhu, A.X., Finn, R.S., Edeline, J., et al. (2018) Pembroli-zumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib (KEYNOTE-224): A Non-Randomised, Open-Label Phase 2 Trial. The Lancet Oncology, 19, 940-952. https://doi.org/10.1016/S1470-2045(18)30351-6
|
[33]
|
Abou-Alfa, G.K., Meyer, T., Cheng, A.L., et al. (2018) Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. The New England Journal of Medi-cine, 379, 54-63.
https://doi.org/10.1056/NEJMoa1717002
|
[34]
|
Zhu, A.X., Park, J.O., Ryoo, B.Y., et al. (2015) Ramucirumab ver-sus Placebo as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma Following First-Line Thera-py with Sorafenib (REACH): A Randomised, Double-Blind, Multicentre, Phase 3 Trial. The Lancet Oncology, 16, 859-870.
https://doi.org/10.1016/S1470-2045(15)00050-9
|
[35]
|
Zhu, A.X., Kang, Y.K., Yen, C.J., et al. (2019) Ramu-cirumab after Sorafenib in Patients with Advanced Hepatocellular Carcinoma and Increased α-Fetoprotein Concentrations (REACH-2): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet Oncology, 20, 282-296. https://doi.org/10.1016/S1470-2045(18)30937-9
|
[36]
|
European Association for the Study of the Liver (2018) EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. Journal of Hepatology, 69, 182-236.
|